Key Highlights:

  • Revenue came in at.
  • Combined 2027 Revenue Guidance totaled well in excess of USD 400 million with double-digit growth.
  • Surgical Revenue stood at USD 39.3 million, increasing 15% year over year driven by balanced growth in sheet and particulate.
  • Wound Revenue was reported at USD 25.1 million, a decline of 61% year over year resulting from Medicare reimbursement changes.

MiMedx Group, Inc (NASDAQ:MDXG) is scheduled to report third quarter results on Wednesday, Oct. 28, after the market close. Consensus estimates call for adjusted earnings per share of USD 0.00 on revenue of USD 68.56 million, against a market capitalization of USD 561.18 million.

In the most recently reported quarter, Revenue came in at.

Sequential Revenue Growth and Other Business Trends

Sequential Revenue Growth came in at 9% from the first quarter to the second quarter, reflecting early stabilization in the wound care market. June Net Sales totaled USD 24 million, representing the highest monthly total for the calendar year to date. Wound Care Volume grew 22% sequentially from the first quarter, with wound care center volume growing 44% over the same period. GAAP Gross Margin was reported at 69% compared to 81.1% in the prior year period, driven by lower pricing in the Wound segment and unfavorable product mix.

What Management Guided

2026 Standalone Revenue Guidance came in at USD 260 million to USD 290 million. 2026 Standalone Adjusted EBITDA Guidance totaled approaching breakeven on a full-year basis.

Adjusted Gross Margin and Capital Position

Adjusted Gross Margin came in at 73.7%, down from 83.6% in the second quarter of 2025. Selling, General and Administrative Expense totaled USD 59.8 million, a decrease from USD 64.2 million due to cost reduction initiatives and lower commissions. Bad Debt Expense stood at USD 5 million increase year over year, resulting from credit deterioration in a limited number of legacy private office accounts. Adjusted EBITDA was reported at negative USD 8.1 million, compared to positive USD 24.2 million in the prior year period. GAAP Net Loss came in at USD 14.8 million, or USD 0.10 per diluted share, versus a net income of USD 9.6 million in the prior year period.

Cash Position and Additional Detail

Cash Position came in at USD 119 million in net cash at quarter end, an increase of USD 19 million compared to the prior year period. Share Repurchases totaled USD 13 million deployed to repurchase approximately 3.5 million shares at an average price of USD 3.67 before the program was terminated. Sanara Acquisition Value stood at USD 35 per share, consisting of USD 33 in cash and 0.4735 shares of MiMedx common stock per Sanara share. Total Enterprise Value was reported at approximately USD 350 million for the Sanara MedTech acquisition, which is expected to close by year-end. Cost Synergies came in at at least USD 20 million in annualized savings, with more than 50% expected to come from general and administrative overlaps.

Figures to Follow in the Release

Investors can watch third quarter results against the figures management has already put on record, including the following: Combined 2027 Revenue Guidance came in at well in excess of USD 400 million with double-digit growth.